COVID-19: a case for inhibiting IL-17?
- PMID: 32358580
- PMCID: PMC7194244
- DOI: 10.1038/s41577-020-0328-z
COVID-19: a case for inhibiting IL-17?
Abstract
IL-17 and IL-17 receptor inhibitors boast an impressive safety history and are widely available. Here, we argue that targeting IL-17 is immunologically plausible as a strategy to prevent acute respiratory distress syndrome (ARDS) in coronavirus disease 2019 (COVID-19) and discuss why we think that a clinical trial of a drug in this class could be a logical addition to the effort to find effective therapies.
Conflict of interest statement
The authors declare no competing interests.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
